Challenges and Innovations in Managing Warfarin Therapy: Insights into Pregnancy, Genetics, and Modern Monitoring

Abstract

Objective: Warfarin stays an significantly used anticoagulant for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves. However, its narrow therapeutic index, genetic variability, and teratogenicity during pregnancy complicate its management. Recent advancements in pharmacogenomics and INR monitoring offer new possibilities to enhance patient outcomes.

Methods: A comprehensive narrative review was performed by using PubMed, Scopus, Embase, and Google Scholar (2000–2025). The keywords encompassed warfarin, pregnancy, pharmacogenetics, and INR self-monitoring. The assessment covered research focusing on genetic factors, safety throughout pregnancy, and improvements in INR monitoring.

Results: Out of 1,245 articles recognized, 30 outstanding studies have been selected. Evidence shows that the variants of CYP2C9, VKORC1, and CYP4F2 have a significant impact on dosing necessities. During pregnancy, warfarin poses an expanded risk to the fetus; however, LMWH bridging techniques assist to mitigate complications. Home INR self-monitoring out has been shown to enhance the time spent in the healing variety and decrease thromboembolic occasions when as compared to tracking conducted in clinics.

Conclusion: Management of Warfarin remedy necessitates a customized approach, specifically for pregnant women and people with genetic sensitivities. The implementation of pharmacogenetic dosing algorithms and domestic INR monitoring are significant improvements aimed toward improving protection and effectiveness. A collaborative, multidisciplinary method is vital for accomplishing the great feasible patient outcomes.